VIENNALAB - Established innovations in diagnostics

Monoclonal antibody therapies targeting EGFR work exceptionally well in metastatic colorectal cancer. However, certain mutations in the KRAS and BRAF gene can prevent success of these therapies. The KRAS–BRAF StripAssay® identifies the most relevant KRAS and BRAF mutations.

Monoclonal antibody therapies targeting EGFR work exceptionally well in metastatic colorectal cancer. However, certain mutations in the KRAS and BRAF gene can prevent success of these therapies.

The KRAS–BRAF StripAssay® identifies the most relevant KRAS and BRAF mutations.

KRAS-BRAF Mutations

  • Epidermal Growth Factor (EGF) activates cell proliferation by binding to the EGF-Receptor (EGFR). This triggers a signal transduction pathway that includes the KRAS and BRAF proteins.
  • Inhibiting EGFR with monoclonal EGFR antibodies or small molecule therapeutics prevents activation of the relevant signal transduction pathway.
  • However, certain mutations in KRAS and BRAF result in permanent activation of parts of this pathway, rendering anti-EGFR therapies ineffective.
  • Identification of KRAS and BRAF mutations thus allows patient-specific treatment and prediction of tumor progression.

Product Details

KRAS-BRAF StripAssay® ref5-580